| Literature DB >> 35755456 |
Patrick Eberechi Akpaka1,2, Khamiya Henry1, Reinand Thompson2, Chandrashekhar Unakal2.
Abstract
Objective: To assess colonization of Streptococcus agalactiae [group B streptococcus (GBS)], and delineate capsular serotype distribution and antibiotic susceptibility profiles among pregnant women in Trinidad and Tobago.Entities:
Keywords: Polymerase chain reaction; Serotype carriage; Streptococcus agalactiae; Susceptibility profiles; Trinidad and Tobago
Year: 2022 PMID: 35755456 PMCID: PMC9216269 DOI: 10.1016/j.ijregi.2022.03.010
Source DB: PubMed Journal: IJID Reg ISSN: 2772-7076
Primer pairs for Streptococcus agalactiae serotyping (Hickman et al., 1999).
| Primer name | Sequence | Gene target (s) | Amplicon size (s), bp |
|---|---|---|---|
| Ia-F | GGTCAGACTGGATTAATGGTATGC | cps1aH | 521 and 1,826 |
| Ia-R | GTAGAAATAGCCTATATACGTTGAATGC | cps1aH | |
| Ib-F | TAAACGAGAATGGAATATCACAAACC | cps1bJ | 770 |
| Ib-R | GAATTAACTTCAATCCCTAAACAATATCG | cpsIbK | |
| II-F | GCTTCAGTAAGTATTGTAAGACGATAG | cps2K | 397 |
| II-R | TTCTCTAGGAAATCAAATAATTCTATAGGG | cps2K | |
| III-F | TCCGTACTACAACAGACTCATCC | cps1a/2/3I | 1,826 |
| III-R | AGTAACCGTCCATACATTCTATAAGC | cps1a/2/3J | |
| IV-F | GGTGGTAATCCTAAGAGTGAACTGT | cps4N | 578 |
| IV-R | CCTCCCCAATTTCGTCCATAATGGT | cps4N | |
| V-F | GAGGCCAATCAGTTGCACGTAA | cps5O | 701 |
| V-R | AACCTTCTCCTTCACACTAATCCT | cps5O | |
| VI-F | GGACTTGAGATGGCAGAAGGTGAA | cps6I | 487 |
| VI-R | CTGTCGGACTATCCTGATGAATCTC | cps6I | |
| VII-F | CCTGGAGAGAACAATGTCCAGAT | cps7M | 371 |
| VII-R | GCTGGTCGTGATTTCTACACA | cps7M | |
| VIII-F | AGGTCAACCACTATATAGCGA | cps8J | 282 |
Characteristics of study participants with Streptococcus agalactiae carriage among a cross-section of pregnant women attending antenatal clinics in Trinidad and Tobago (%).
| Characteristics | Frequency | |
|---|---|---|
| Ethnicity | 0.301 | |
| Afro-Trinidadian | 32 (44.4) | |
| Indo-Trinidadian | 23 (32) | |
| Mixed | 15 (20.8) | |
| Other | 2 (2.8) | |
| Pregnancy history | 0.035 | |
| Primigravida | 36 (50) | |
| Multigravida | 36 (50) | |
| Marital status | 0.006 | |
| Single | 29 (40.2) | |
| Married | 22 (30.6) | |
| Divorced | 0 | |
| Separated | 1 (1.4) | |
| Common law | 20 (27.8) | |
| Age group | 0.005 | |
| 18–23 | 12 (16.7) | |
| 24–29 | 33 (45.8) | |
| 30–35 | 22 (30.5) | |
| 36–41 | 3 (4.2) | |
| 42–47 | 2 (2.8) | |
| Gestational DM | 0.042 | |
| A | 54 (75) | |
| B | 18 (25) |
DM, diabetes mellitus; A, diabetics colonized with S. agalactiae; B, non-diabetics colonized with S. agalactiae.
P≤0.05 was taken to indicate significance.
Figure 1Results of gel electrophoresis from confirmatory polymerase chain reaction assay targeting the 780-bp atr gene of the Streptococcus agalactiae isolates from Trinidad and Tobago. Lane 1, DNA marker; lane 2, Enterococcus faecalis ATCC 29212 (negative control); lane 3, Streptococcus agalactiae ATCC 12386 (positive control), lanes 4–7, Streptococcus agalactiae isolates with 780 bp.
Figure 2Polymerase chain reaction products of Streptococcus agalactiae serotypes recovered from vaginal swabs of antenatal patients from Trinidad and Tobago. Lane 1, DNA marker; Lanes 2–9 Streptococcus agalactiae isolates showing predominantly serotype II.
Antibiotic susceptibility pattern of Streptococcus agalactiae isolates from women attending antenatal clinics in Trinidad and Tobago.
| Antibiotics | Susceptible (%) | Resistant (%) |
|---|---|---|
| Ampicillin | 25 (34.7) | 47 (65.3) |
| AMC | 45 (62.5) | 27 (37.5) |
| Azithromycin | 69 (95.8) | 3 (4.2) |
| Ceftriaxone | 68 (94.4) | 4 (5.6) |
| Cefuroxime | 68 (94.4) | 4 (5.6) |
| Ciprofloxacin | 66 (91.7) | 6 (8.3) |
| Clindamycin | 65 (90.3) | 7 (9.7) |
| Ertapenem | 65 (90.3) | 7 (9.7) |
| Erythromycin | 50 (69.4) | 22 (30.6) |
| Imipenem | 67 (93.1) | 5 (6.9) |
| Levofloxacin | 66 (91.7) | 6 (8.3) |
| Norfloxacin | 65 (90.3) | 7 (9.7) |
| Meropenem | 72 (100) | 0 |
| Nitrofurantoin | 39 (54.2) | 33 (45.8) |
| SXT | 30 (41.7) | 42 (58.3) |
| Tetracycline | 2 (2.8) | 70 (97.2) |
| TZP | 70 (97.2) | 2 (2.8) |
| Vancomycin | 72 (100) | 0 |
AMC, amoxicillin/clavulanic acid; SXT, trimethroprim-sulphamethaxole; TZP, piperacillin-tazobactam.